Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Chemotherapy and Radiotherapy in Anal Canal Squamous Carcinoma
NCT05060471Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in anal canal squamous cell carcinoma (SCCA), sponsored by Sun Yat-sen University. Started Oct 2021; status: completed.
02
Drugs
toripalimab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT05060471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060471.